Latest / Lung Cancer Considered
AEGEAN and Beyond: Perioperative Immunotherapy for NSCLC
Lung Cancer Considered host Dr. Narjust Florez leads an informed discussion on the AEGEAN Trial, which explored neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resected NSCLC.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.